Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.76 |
| ▸ | NPC1 | O15118 | 10/20 | 0.76 |
| ▸ | RAB9A | P51151 | 10/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.76 |
| ▸ | MAPT | P10636 | 8/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.69 |
| ▸ | RELA | Q04206 | 3/20 | 0.69 |
| ▸ | SCD | O00767 | 7/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212825 | 0.90 | KMT2A (0.76) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4919654 | 0.85 | SCD (0.88) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10081066 | 0.84 | PIK3CG (0.68) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16562121 | 0.83 | SCD (0.89) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2759505 | 0.83 | MAPT (0.86) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1064848 | 0.82 | HDAC1 (0.68) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1761313 | 0.82 | SMN1; SMN2 (0.77) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14880886 | 0.82 | MAPT (0.84) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1821539 | 0.82 | PDE10A (0.67) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1307056 | 0.81 | MAPT (0.82) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | MEN1 2386/4885KMT2A 68/4885NPC1 1293/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | MEN1 2075/4885KMT2A 123/4885NPC1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.